Liposomal CBD Injection Technology (LPT-CBD) patent was allowed in Japan

Innovative Chronic Pain Treatment Receives allowance for IP Protection in Japan's World Third Largest Pharmaceutical Market

HERZLIYA, Israel and CALGARY, AB, Oct. 15, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that its patent for LPT-CBD was allowed in Japan and will be officially granted upon completion of the administrative process. The patent covers a prolonged-release liposome-based formulation that encapsulates cannabinoids.

This patent protects Innocan's LPT-CBD formulation designed for the sustained release of synthetic CBD into the bloodstream. The newly allowed patent is part of a broad international patent family currently under examination in multiple jurisdictions worldwide. It joins the company's granted patent in India, further strengthening Innocan global intellectual property portfolio and ensuring maximum protection and enforceability. With Japan being the world's third-largest pharmaceutical market, valued at approximately $102 billion (1), this achievement represents an important milestone for Innocan in advancing LPT-CBD as a leading non-opioid solution for chronic pain management.

Developed jointly in collaboration with Professor Chezy Barenholz and Dr. Ahuva Cern from the Hebrew University in Jerusalem, the liposomal drug delivery platform allows for prolonged exposure and maximizes the bioavailability and therapeutic effects of CBD. LPT-CBD has demonstrated prolonged pharmacokinetics and pain-relief effects lasting up to four weeks, supported by multiple preclinical studies. Following a successful pre-IND meeting, the U.S. Food and Drug Administration (FDA) provided positive feedback to advance the development of LPT-CBD as a non-opioid alternative for chronic pain management.

"We are thrilled to receive this patent allowance for our proprietary technology," said Iris Bincovich, Chief Executive Officer of Innocan Pharma. "This allowance marks our second patent to be granted for LPT-CBD, following the one granted in India, further strengthening our innovation and global IP position. We look forward to a series of additional patent approvals worldwide."

Professor Chezy Barenholz the Head of our Advisory Board stated, "The allowance of this patent provides strong evidence to the dedication and expertise of our development teams in driving innovation. LPT-CBD is the first drug product in our pipeline that we are currently advancing under this intellectual property portfolio."  

Dr. Eyal Kalo, Vice President of R&D added, "LPT-CBD is progressing under a streamlined development plan toward FDA approval. "We are extremely proud of this patent allowance and remain dedicated to advancing LPT-CBD as a non-opioid alternative for chronic pain management."

Reference

(1) https://www.fortunebusinessinsights.com/japan-pharmaceuticals-market-113904

About Innocan 

Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment, Innocan focuses on advanced, targeted online sales, through its BI Sky Global Ltd. subsidiary. www.innocanpharma.com 

For further information, please contact:
Innocan Pharma Corporation:
Iris Bincovich, CEO
[phone]
[phone]
[phone]
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution Regarding Forward-Looking Information

Certain information set forth in this news release is forward-looking information within the meaning of applicable securities laws. For example, the Company is using forward-looking statements when it discusses the potential of the Company's LPT-CBD technology as an innovative solution for pain management in patients. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Logo - https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg

SOURCE Innocan Pharma Corporation